Formycon AG | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
7,767.00
860.30
577.50
4,066.10
1,581.40
7,098.60
Depreciation, Depletion & Amortization
1,103.00
1,071.90
934.80
698.90
784.80
904.30
Other Funds
13,890.00
7.60
-
-
-
34.40
Funds from Operations
6,664.00
1,951.60
1,669.10
3,338.30
785.00
8,037.30
Changes in Working Capital
9,959.00
1,983.60
1,110.80
1,691.60
3,426.90
5,234
Net Operating Cash Flow
16,623.00
32.00
558.30
5,029.90
4,211.90
13,271.30
Capital Expenditures
144.00
570.80
669.90
1,325.30
432.30
Sale of Fixed Assets & Businesses
-
-
-
0.30
-
Purchase/Sale of Investments
-
-
-
61.90
78.70
Net Investing Cash Flow
144.00
570.80
667.30
1,386.90
511.00
Net Financing Cash Flow
17,435.00
7.60
11,182.40
86.50
6,233.50
Net Change in Cash
668.00
610.40
11,073.40
6,330.30
1,510.60
Free Cash Flow
16,767.00
602.80
111.70
6,355.20
4,644.20
Other Sources
-
-
2.60
-
-
Change in Capital Stock
3,545.00
-
11,182.40
86.50
6,233.50

About Formycon

View Profile
Address
Fraunhoferstraße 15
Munich Bayern (Bavaria) 82152
Germany
Employees -
Website http://formycon.com
Updated 07/08/2019
Formycon AG engages in the manufacture of biosimilar drugs and formulations. Its product candidates include FYB201, FYB202, FYB203, and FYB205 which focusoin the opthalmology and immunology disease areas. The company was founded by Friedrich Wilhelm Steinweg and Nicolas Combé in 2007 and is headquartered in Munich, Germany.